Alcon acquired the intraocular lens developer in a $285m deal that follows $106m in funding from investors including its parent company Novartis as well as Johnson & Johnson and Medtronic.

The sickle cell disease therapy developer boosted its overall funding to $94m in a round backed by Lundbeck, Pfizer and Alexandria Real Estate Equities.

CWRU-licensed NervGen Pharma floated at the top of its range on the TSX Venture Exchange, with the proceeds earmarked to push its lead candidate for spinal cord injury into the clinic.

Cystic fibrosis drug developer Respirion Pharmaceuticals has spun out from Telethon Kids Institute with capital from an Australian government-backed initiative.

The central nervous system disorder drug developer has now raised more than $118m, with PureTech Health and Pivotal BioVenture Partners among the investors in its latest round.

Hearst Health Ventures contributed to a BVP-led round that boosted the health benefits data platform's total funding to about $51m.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

New York Genome Center-founded Gencove has added $3m from investors including Alexandria Venture Investments to bring its genomics testing kit to new markets.

The medical research services provider collected funding from investors including Cash Capital, an investment arm of CAS which previously backed a series A.

The healthcare research platform has increased its total funding to $102m following a Merck GHI-led round that included Itochu Technology Ventures and Mitsui.